Kisqali (ribociclib) has received several FDA approvals, primarily for specific types of breast cancer.
Initial FDA Approval and Later Expansions for Kisqali
Kisqali first gained FDA approval in March 2017 [1]. This initial approval was for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor [1].
The drug later received approval for a broader patient population. In July 2020, the FDA approved Kisqali in combination with fulvestrant for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer, as initial endocrine-based therapy or after disease progression following endocrine therapy [2]. Subsequently, in December 2020, the FDA approved Kisqali in combination with an aromatase inhibitor for postmenopausal women with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer as initial endocrine therapy [3].
In February 2022, Kisqali received a significant expansion of its indication. The FDA approved Kisqali in combination with endocrine therapy for the treatment of adult patients with hormone receptor (HR)-positive, HER2-negative, advanced or metastatic breast cancer, as their first endocrine-based therapy [4]. This approval was based on the MONALEESA-7 trial, which demonstrated a significant improvement in progression-free survival (PFS) in premenopausal women [4].
How Does Kisqali Work in Treating Breast Cancer?
Kisqali is a cyclin-dependent kinase (CDK) inhibitor [1]. Specifically, it targets CDK4 and CDK6, enzymes that play a role in cell division. By inhibiting these kinases, Kisqali helps to stop cancer cells from growing and dividing [1]. It is typically used in combination with other treatments, such as endocrine therapy (like aromatase inhibitors or fulvestrant), to enhance its effectiveness in treating HR-positive, HER2-negative advanced or metastatic breast cancer [1][4].
When Does Kisqali's Patent Protection Expire?
Patent expiration dates for pharmaceutical drugs are complex and can be influenced by various factors, including new patents for different formulations or methods of use, and any legal challenges. Information on specific patent expiry dates can be found on specialized databases. For detailed information on Kisqali's patent landscape and potential future generic competition, resources like DrugPatentWatch.com can be consulted [5].
What Are the Main Side Effects of Kisqali?
Common side effects associated with Kisqali treatment include neutropenia (low white blood cell count), nausea, vomiting, diarrhea, fatigue, hair loss, and abnormalities in liver function tests [1][4]. Close monitoring by a healthcare provider is essential to manage these potential side effects.
Who Manufactures Kisqali?
Kisqali is manufactured by Novartis [1].
What is the Cost of Kisqali?
The cost of Kisqali can vary significantly based on factors such as dosage, insurance coverage, and geographic location. For the most current pricing information, it is advisable to consult with healthcare providers or pharmaceutical assistance programs.
What Clinical Trials Support Kisqali's Approval?
Key clinical trials that have supported Kisqali's FDA approvals include the MONALEESA program. For instance, the MONALEESA-7 trial was pivotal in demonstrating the efficacy of Kisqali in premenopausal women [4]. Other trials within the MONALEESA series have contributed to understanding its effectiveness in different patient populations and treatment settings [1][2][3].
Are There Alternatives to Kisqali for Advanced Breast Cancer?
Several other treatments are available for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. These include other CDK4/6 inhibitors such as Ibrance (palbociclib) and Verzenio (abemaciclib) [6]. The choice of treatment depends on individual patient characteristics, prior therapies, and physician recommendations.
---
Sources:
[1] FDA. (2017, March 3). FDA approves Kisqali (ribociclib) plus an aromatase inhibitor for postmenopausal women with HR+, HER2- advanced breast cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-kisqali-ribociclib-plus-aromatase-inhibitor-postmenopausal-women-hr-her2-advanced-breast
[2] FDA. (2020, July 7). FDA approves Kisqali (ribociclib) plus fulvestrant for patients with HR+, HER2- advanced or metastatic breast cancer. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-kisqali-ribociclib-plus-fulvestrant-patients-hr-her2-advanced-or-metastatic-breast-cancer
[3] FDA. (2020, December 18). FDA approves Kisqali (ribociclib) plus an aromatase inhibitor for postmenopausal women with HR+, HER2- advanced or metastatic breast cancer. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-kisqali-ribociclib-plus-aromatase-inhibitor-postmenopausal-women-hr-her2-advanced-or-metastatic-breast-cancer
[4] FDA. (2022, February 28). FDA approves Kisqali (ribociclib) in combination with endocrine therapy for HR+, HER2- advanced or metastatic breast cancer. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-kisqali-ribociclib-combination-endocrine-therapy-hr-her2-advanced-or-metastatic-breast-cancer
[5] DrugPatentWatch. (n.d.). Ribociclib Patents. https://drugpatentwatch.com/ribociclib
[6] National Cancer Institute. (2024, February 8). CDK4/6 Inhibitors. https://www.cancer.gov/about-cancer/treatment/drugs/cdk4-6-inhibitors